SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (2163)10/6/1997 7:29:00 PM
From: Joe E.   of 6136
 
Henry, further your "Were there additional studies that used Viracept
as the first PI?"

Here is the URL that most recently discusses the information in my earlier post. It involves a study by Dr. Henry, and another study involving Crixivan. I don't know whether this is totally responsive to your question, but on rereading this article it does seem to support my recollection that failure on Viracept may not be as bad as failure on Crixivan. Also, perhaps this is a different study by Dr. Henry from the one you mention, because it does not seem to match your number of 4 of 7 failing.

URL:
medscape.com

Quote(well maybe upload in your parlance):
"Seven of 9 patients (77%) suppressed below the detection
limit. Two did not, with 3.1 log and 4.4 log copies being the
lowest suppression achieved.

Looking at differences in the study populations, 10 of 12
relatively naive patients had a rapid drop in viral load
amounting to greater than 1.5 log reduction by week 4. Viral
RNA levels remained below 500 copies/mm3 for 6 of these
patients through 16 weeks. The more ARV experienced
patients showed a lesser reduction in vRNA, amounting to
about 1 log at 4 weeks.

The researchers conclude that preliminary results suggest
that most subjects failing ART therapy that includes nelfinavir
can have their vRNA suppressed below the detection limit
by a ritonavir/saquinavir-based regimen over a short term.
Maintaining the suppression"
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News